## KIT-Targeted Therapy in GIST **Key Point:** Imatinib mesylate is the first-line tyrosine kinase inhibitor for KIT-mutant gastrointestinal stromal tumors (GISTs), both localized and metastatic. ### KIT Oncogene in GIST Pathogenesis - KIT (CD117) is a receptor tyrosine kinase mutated in ~95% of GISTs - Mutations (exon 11 > exon 9) cause constitutive kinase activation - Drives uncontrolled proliferation of interstitial cells of Cajal - KIT positivity is diagnostic (IHC CD117+) ### Imatinib Mechanism in GIST 1. Selectively inhibits KIT tyrosine kinase 2. Blocks downstream signaling (PI3K/Akt, MAPK) 3. Induces apoptosis in GIST cells 4. Standard dose: 400 mg daily for localized/metastatic disease **High-Yield:** Imatinib is the only drug proven to improve overall survival in GIST and is indicated for: - Neoadjuvant therapy (downstaging) - Adjuvant therapy (high-risk localized GIST) - Metastatic/unresectable GIST ### Clinical Evidence | Setting | Benefit of Imatinib | |---------|--------------------| | Metastatic GIST | Median OS ~55 months vs. 20 months (historical controls) | | Adjuvant (high-risk) | 3-year recurrence-free survival improvement | | Neoadjuvant | Downsizing, improved resectability | **Clinical Pearl:** Resistance to imatinib develops in ~10–15% of patients, often due to secondary KIT mutations (exon 13, 14, 17). Sunitinib is the second-line option for imatinib-resistant GIST. ### Comparison with Alternatives | Agent | Role | Limitation | |-------|------|------------| | Imatinib | First-line TKI for KIT+ GIST | Resistance in minority; requires monitoring | | Sunitinib | Second-line (imatinib resistance) | Not first-line; broader spectrum TKI | | Doxorubicin | Chemotherapy (pre-TKI era) | Ineffective; poor outcomes in GIST | | 5-FU | Chemotherapy for GI cancers | Not indicated for GIST; lacks KIT targeting | **Mnemonic:** **KIT-I** = KIT mutations require Imatinib in GIST.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.